♥

Cipla Limited

ISIN : INE059A01026
NSE : CIPLA
BSE : 500087
Face Value : 2
Industry : Pharmaceuticals & Drugs

EPS : 51.01
EPS (TTM) : 55.38
Price to Earning (P/E) : 28.27
Book Value : 329.72
Price to Bookvalue (P/B) : 4.37
Dividend Yield : 1 %
Return on Equity (ROE) : 16.63 %
Return on Capital Employed (ROCE) : 22.77 %

Cipla Limited share price (02-Apr-2026)
National Stock Exchange NSE
Open / Close	0 - 0 NAN %
Low / High	0 - 0 NAN %
Trade Volume	0
52 Week Low / High	0 - 0 NAN %
Bombay Stock Exchange BSE
Open / Close	1193.1 - 1193.4 0 %
Low / High	1165.55 - 1196.8 2.7 %
Trade Volume	1.02 Lk
52 Week Low / High	1165.55 - 1672.2 43.5 %

YOU MAY ALSO LIKE

How much money do you need to retire
Know how much money do you need to retire, before how much to invest ?
Share Market basics for beginners
Share Market jargons in simple terms
Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE
CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator
Stock market course tutorial
Stock Market Investment Course explained in simple words.
High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE

Consolidated Standalone

CONSOLIDATED QUARTERLY RESULT FOR CIPLA LIMITED

Date End	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	53751.9	58285.4	58100.9	57393	63288.9	66781.5	66038.1	61632.4	66939.4	70510.2
Total Income	54786.2	59514.9	59245.3	58739.3	64651.8	68544.7	67884.4	64125.7	68541.3	72416.3
Total Expenditure	42318.4	45262.1	44025.4	45655.6	48349.8	49444	48562.8	48473.8	49781.4	51654.3
Other Income	1034.3	1229.5	1144.4	1346.3	1362.9	1763.2	1846.3	2493.3	1601.9	1906.1
Operating Profit	12467.8	14252.8	15219.9	13083.7	16302	19100.7	19321.6	15651.9	18759.9	20762
Interest	178.1	255.5	318.2	343.6	163.9	258	301	175.9	179.5	154
Exceptional Items				-1824.2			-1948.2
PBDT	12289.7	13997.3	14901.7	10915.9	16138.1	18842.7	17072.4	15476	18580.4	20608
Depreciation	2544.1	2993.7	2721.1	3462.2	2392.1	2900.4	2334.3	2883.4	2466.8	2717.4
Profit Before Tax	9745.6	11003.6	12180.6	7453.7	13746	15942.3	14738.1	12592.6	16113.6	17890.6
Tax	2680	3026	4100.1	2222.5	3780.2	4384.1	4053	3248.6	4350.7	4830.4
Profit After Tax	7065.6	7977.6	8080.5	5231.2	9965.8	11558.2	10685.1	9344	11762.9	13060.2
Net Profit	7065.6	7977.6	8080.5	5231.2	9965.8	11558.2	10685.1	9344	11762.9	13060.2
Equity Capital	1613.8	1614	1614.3	1614.3	1614.5	1614.7	1614.7	1614.7	1615	1615.1
Face Value (IN RS)	2	2	2	2	2	2	2	2	2	2
Calculated EPS	8.51	9.78	9.92	6.51	12.33	14.01	13.08	11.63	14.58	16.13
Diluted Eps After Extraordinary Items	8.5	9.77	9.92	6.51	12.33	14	13.07	11.62	14.57	16.12
Diluted Eps Before Extraordinary Items	8.5	9.77	9.92	6.51	12.33	14	13.07	11.62	14.57	16.12

STANDALONE QUARTERLY RESULT FOR CIPLA LIMITED

Date End	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	31571.3	41512.7	38994.5	38937.4	43181.9	46647.2	43813.3	40366.6	45010.5	47750.3
Total Income	32748.1	42435.5	40265.7	40134.5	44761.7	48698.1	45503.1	45752.7	47145.7	50641.7
Total Expenditure	22997.5	30902.2	29613.4	30939.6	31135	32856	30254.7	32087.7	31411.9	33369.9
Other Income	1176.8	922.8	1271.2	1197.1	1579.8	2050.9	1689.8	5386.1	2135.2	2891.4
Operating Profit	9750.6	11533.3	10652.3	9194.9	13626.7	15842.1	15248.4	13665	15733.8	17271.8
Interest	22.1	75	68.5	104.6	3.1	78	90.6	54.5	50.7	30
Exceptional Items				-1859
PBDT	9728.5	11458.3	10583.8	7231.3	13623.6	15764.1	15157.8	13610.5	15683.1	17241.8
Depreciation	1074.6	1760.1	1299.6	1615.8	1359.5	1798.1	1350.2	1368.1	1378.6	1457.1
Profit Before Tax	8653.9	9698.2	9284.2	5615.5	12264.1	13966	13807.6	12242.4	14304.5	15784.7
Tax	2213.9	2646.3	2499	2060.6	3313.9	3669.1	3630	2422.1	3745.1	4003.1
Profit After Tax	6440	7051.9	6785.2	3554.9	8950.2	10296.9	10177.6	9820.3	10559.4	11781.6
Net Profit	7591.6	7203	6785.2	3554.9	8950.2	10296.9	11141.4	10384	10559.4	11781.6
Equity Capital	1613.8	1614	1614.3	1614.3	1614.5	1614.7	1614.7	1614.7	1615	1615.1
Face Value (IN RS)	2	2	2	2	2	2	2	2	2	2
Calculated EPS	7.98	8.74	8.41	4.4	11.09	12.75	12.61	12.16	13.08	14.59
Diluted Eps After Extraordinary Items	7.97	8.73	8.4	4.4	11.08	12.75	12.6	12.15	13.07	14.58
Diluted Eps Before Extraordinary Items	7.97	8.73	8.4	4.4	11.08	12.75	12.6	12.15	13.07	14.58

Consolidated Standalone

CONSOLIDATED ANNUAL RESULT FOR CIPLA LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	217633	227531	257741
Total Income	220442	232286	265207
Total Expenditure	172106	177262	194830
Other Income	2809.1	4754.5	7465.7
Operating Profit	48336.9	55024.2	70376.2
Interest	1063.5	1095.4	898.8
Exceptional Items	-1821.2	-1824.2	-1948.2
PBDT	45452.2	52104.6	67529.2
Depreciation	10519.5	11721.1	10510.2
Profit Before Tax	34932.7	40383.5	57019
Tax	9338	12028.6	15465.9
Profit After Tax	25594.7	28354.9	41553.1
Net Profit	25594.7	28354.9	41553.1
Equity Capital	1613.6	1614.3	1614.7
Face Value (IN RS)	2	2	2
Reserves	206803	232464	265450
Calculated EPS	31.19	34.71	51.05
Diluted Eps After Extraordinary Items	31.17	34.69	51.01
Diluted Eps Before Extraordinary Items	31.17	34.69	51.01

STANDALONE ANNUAL RESULT FOR CIPLA LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	130918	157906	165743
Total Income	137585	162474	176450
Total Expenditure	97253.2	119980	120902
Other Income	6667	4567.9	10706.6
Operating Profit	40331.7	42493.7	55548.1
Interest	269.3	270.2	202.5
Exceptional Items		-1859
PBDT	40062.4	40364.5	55345.6
Depreciation	4600.1	5959.1	5875.9
Profit Before Tax	35462.3	34405.4	49469.7
Tax	8568.4	9710.1	12327.8
Profit After Tax	26893.9	24695.3	37141.9
Net Profit	29579.3	25134.7	40772.5
Equity Capital	1613.6	1614.3	1614.7
Face Value (IN RS)	2	2	2
Reserves	223522	244767	278124
Calculated EPS	33.33	30.6	46
Diluted Eps After Extraordinary Items	33.3	30.58	45.97
Diluted Eps Before Extraordinary Items	33.3	30.58	45.97

Consolidated Standalone

CONSOLIDATED PROFIT / LOSS FOR CIPLA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	28227.3 Cr	29719.2 Cr	30937.7 Cr	35415 Cr
Sales	28056.2 Cr	29579.2 Cr	30657.7 Cr	35087.6 Cr
Processing Charges / Service Income	8.31 Cr	9.4 Cr	7.62 Cr	8.18 Cr
Net Sales	19159.6 Cr	21763.3 Cr	22753.1 Cr	25774.1 Cr
Increase/Decrease in Stock	-192.71 Cr	-724.69 Cr	-96 Cr	63.03 Cr
Raw Material Consumed	7544.6 Cr	9220.29 Cr	8348.28 Cr	8756.54 Cr
Opening Raw Materials	1762.47 Cr	1795.44 Cr	1701.19 Cr	1615.83 Cr
Purchases Raw Materials	4919.4 Cr	5438.88 Cr	5434.26 Cr	5224.15 Cr
Closing Raw Materials	1795.44 Cr	1701.19 Cr	1615.83 Cr	1619.47 Cr
Other Direct Purchases / Brought in cost	2658.17 Cr	3687.16 Cr	2828.66 Cr	3536.03 Cr
Power & Fuel Cost	308.26 Cr	331.03 Cr	353.61 Cr	364.84 Cr
Electricity & Power	308.26 Cr	331.03 Cr	353.61 Cr	364.84 Cr
Employee Cost	3251.83 Cr	3529.91 Cr	3830.08 Cr	4310.04 Cr
Salaries, Wages & Bonus	2929.18 Cr	3163.06 Cr	3407.52 Cr	3855.36 Cr
Contributions to EPF & Pension Funds	148.16 Cr	164.14 Cr	163.81 Cr	171.05 Cr
Workmen and Staff Welfare Expenses	154.95 Cr	178.59 Cr	219.71 Cr	237.47 Cr
Other Manufacturing Expenses	1206.33 Cr	1453.22 Cr	1589.9 Cr	1779.35 Cr
Sub-contracted / Out sourced services	250.63 Cr	258.81 Cr	293.27 Cr	351.7 Cr
Repairs and Maintenance	154.48 Cr	194.61 Cr	202.89 Cr	224.38 Cr
General and Administration Expenses	986.01 Cr	1206.07 Cr	1423.23 Cr	1673.94 Cr
Rent , Rates & Taxes	143.92 Cr	178.45 Cr	191.5 Cr	205.9 Cr
Insurance	62.6 Cr	73.65 Cr	79.65 Cr	86.39 Cr
Professional and legal fees	609.29 Cr	698.81 Cr	803.73 Cr	928.48 Cr
Traveling and conveyance	126.88 Cr	203.32 Cr	290.94 Cr	393.33 Cr
Selling and Distribution Expenses	1298.62 Cr	1670 Cr	1694.3 Cr	1724.97 Cr
Advertisement & Sales Promotion	800.43 Cr	1058.83 Cr	1098.18 Cr	1087.41 Cr
Sales Commissions & Incentives	200.51 Cr	260.33 Cr	243.55 Cr	225.62 Cr
Freight and Forwarding	297.68 Cr	350.84 Cr	352.57 Cr	411.94 Cr
Miscellaneous Expenses	572.54 Cr	565.55 Cr	619.43 Cr	810.33 Cr
Provision for doubtful debts	39.48 Cr	0	0	23.51 Cr
Loss on sale of non-trade current investments	3.78 Cr	0	0	0
Total Expenditure	14975.5 Cr	17251.4 Cr	17762.8 Cr	19483 Cr
Other Income	269.77 Cr	321.73 Cr	512.13 Cr	746.57 Cr
Interest Received	47.26 Cr	79.62 Cr	162.24 Cr	219.59 Cr
Dividend Received	21.64 Cr	1 Lk	0	0
Profit on sale of Fixed Assets	3.01 Cr	8.68 Cr	1.58 Cr	3.49 Cr
Profits on sale of Investments	52.79 Cr	77.22 Cr	122.39 Cr	70.15 Cr
Provision Written Back	6 Lk	47.19 Cr	45.76 Cr	17.19 Cr
Foreign Exchange Gains	29.22 Cr	21.62 Cr	65.07 Cr	100.93 Cr
Operating Profit	4453.88 Cr	4833.69 Cr	5502.42 Cr	7037.62 Cr
Interest	160.7 Cr	106.35 Cr	109.54 Cr	89.88 Cr
Interest on Term Loan	117.82 Cr	71.4 Cr	54.25 Cr	38.65 Cr
Bank Charges etc	7.72 Cr	1.5 Cr	1.99 Cr	18.75 Cr
PBDT	4293.18 Cr	4727.34 Cr	5392.88 Cr	6947.74 Cr
Depreciation	1003.12 Cr	1051.95 Cr	1172.11 Cr	1051.02 Cr
Profit Before Taxation & Exceptional Items	3290.06 Cr	3675.39 Cr	4220.77 Cr	5896.72 Cr
Exceptional Income / Expenses	0	-182.12 Cr	-182.42 Cr	-194.82 Cr
Profit Before Tax	3290.06 Cr	3493.27 Cr	4038.35 Cr	5701.9 Cr
Provision for Tax	888.76 Cr	933.8 Cr	1202.86 Cr	1546.59 Cr
Current Income Tax	1052.72 Cr	1136.9 Cr	1264.77 Cr	1696.84 Cr
Deferred Tax	-173.64 Cr	-215.21 Cr	-75.62 Cr	-157.73 Cr
Profit After Tax	2401.3 Cr	2559.47 Cr	2835.49 Cr	4155.31 Cr
Minority Interest	16.36 Cr	-29.9 Cr	-30.98 Cr	-32.17 Cr
Share of Associate	-12.79 Cr	-12.82 Cr	-2.6 Cr	-1.59 Cr
Consolidated Net Profit	2404.87 Cr	2516.75 Cr	2801.91 Cr	4121.55 Cr
Profit Balance B/F	11117.9 Cr	13537 Cr	15669.1 Cr	18057 Cr
Appropriations	13522.8 Cr	16053.7 Cr	18471 Cr	22178.6 Cr
Other Appropriation	-14.23 Cr	384.66 Cr	413.95 Cr	739.8 Cr
Equity Dividend %	250	250	425	650
Earnings Per Share	29.82	31.19	34.71	51.05
Adjusted EPS	29.82	31.19	34.71	51.05

STANDALONE PROFIT / LOSS FOR CIPLA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	14765.1 Cr	14008.5 Cr	16503.6 Cr	17483 Cr
Sales	14474.6 Cr	13744 Cr	15231.8 Cr	15349.8 Cr
Processing Charges / Service Income	89 Lk	3.67 Cr	1.1 Cr	3.08 Cr
Net Sales	13900.6 Cr	13091.8 Cr	15790.6 Cr	16574.3 Cr
Increase/Decrease in Stock	-9.93 Cr	-528.4 Cr	205.26 Cr	104.57 Cr
Raw Material Consumed	4082.5 Cr	4468.54 Cr	4155.98 Cr	3784.66 Cr
Opening Raw Materials	1303.88 Cr	1335.23 Cr	1209.41 Cr	1173.74 Cr
Purchases Raw Materials	2266 Cr	1491.87 Cr	2126.92 Cr	1482.86 Cr
Closing Raw Materials	1335.23 Cr	1209.41 Cr	1173.74 Cr	1232.35 Cr
Other Direct Purchases / Brought in cost	1847.85 Cr	2850.85 Cr	1993.39 Cr	2360.41 Cr
Power & Fuel Cost	234.58 Cr	247.58 Cr	257.07 Cr	271.66 Cr
Electricity & Power	234.58 Cr	247.58 Cr	257.07 Cr	271.66 Cr
Employee Cost	2038.88 Cr	1729.16 Cr	2377.27 Cr	2644.21 Cr
Salaries, Wages & Bonus	1835.46 Cr	1522.04 Cr	2129.3 Cr	2373.86 Cr
Contributions to EPF & Pension Funds	95.13 Cr	90.65 Cr	93.51 Cr	101.46 Cr
Workmen and Staff Welfare Expenses	93.51 Cr	96.78 Cr	130.99 Cr	143.82 Cr
Other Manufacturing Expenses	2118.8 Cr	1656.54 Cr	2696.35 Cr	2639.07 Cr
Sub-contracted / Out sourced services	189.43 Cr	180.11 Cr	207.56 Cr	241.35 Cr
Repairs and Maintenance	119.41 Cr	145.81 Cr	156.53 Cr	159.94 Cr
Packing Material Consumed	1027.64 Cr	1150.1 Cr	1340.18 Cr	1192.96 Cr
General and Administration Expenses	714.86 Cr	896.37 Cr	1041.29 Cr	1211.77 Cr
Rent , Rates & Taxes	89.28 Cr	115.32 Cr	123.93 Cr	126.95 Cr
Insurance	38.99 Cr	46.64 Cr	50.44 Cr	48.34 Cr
Professional and legal fees	471.88 Cr	542.9 Cr	594.09 Cr	676.07 Cr
Traveling and conveyance	84.95 Cr	157.4 Cr	234.25 Cr	317.37 Cr
Selling and Distribution Expenses	678.66 Cr	907.4 Cr	890.08 Cr	894.54 Cr
Advertisement & Sales Promotion	289.98 Cr	411.51 Cr	426.09 Cr	411.43 Cr
Sales Commissions & Incentives	180.49 Cr	248.7 Cr	231.39 Cr	197.22 Cr
Freight and Forwarding	208.19 Cr	247.19 Cr	232.6 Cr	285.89 Cr
Miscellaneous Expenses	333.7 Cr	348.13 Cr	382.5 Cr	539.71 Cr
Provision for doubtful debts	19.65 Cr	14.19 Cr	0	9.22 Cr
Total Expenditure	10192 Cr	9725.32 Cr	12005.8 Cr	12090.2 Cr
Other Income	230.28 Cr	666.7 Cr	464.57 Cr	1070.66 Cr
Interest Received	36.42 Cr	72.89 Cr	158.74 Cr	293.82 Cr
Dividend Received	0	403.32 Cr	14.92 Cr	380.69 Cr
Profit on sale of Fixed Assets	3.48 Cr	72 Lk	11.02 Cr	7.5 Cr
Profits on sale of Investments	47.67 Cr	64 Cr	118.13 Cr	48.4 Cr
Provision Written Back	0	0	7.78 Cr	7.03 Cr
Foreign Exchange Gains	44.13 Cr	65.77 Cr	92.59 Cr	46.2 Cr
Operating Profit	3938.81 Cr	4033.17 Cr	4249.37 Cr	5554.81 Cr
Interest	45.07 Cr	26.93 Cr	27.02 Cr	20.25 Cr
PBDT	3893.74 Cr	4006.24 Cr	4222.35 Cr	5534.56 Cr
Depreciation	543.08 Cr	460.01 Cr	595.91 Cr	587.59 Cr
Profit Before Taxation & Exceptional Items	3350.66 Cr	3546.23 Cr	3626.44 Cr	4946.97 Cr
Exceptional Income / Expenses	0	0	-185.9 Cr	0
Profit Before Tax	3350.66 Cr	3546.23 Cr	3440.54 Cr	4946.97 Cr
Provision for Tax	882.38 Cr	856.84 Cr	971.01 Cr	1232.78 Cr
Current Income Tax	904.38 Cr	887.24 Cr	1011.1 Cr	1226.69 Cr
Deferred Tax	-35.3 Cr	-44.74 Cr	-50.48 Cr	-12.3 Cr
Profit After Tax	2468.28 Cr	2689.39 Cr	2469.53 Cr	3714.19 Cr
Extra items	0	268.54 Cr	43.94 Cr	363.06 Cr
Consolidated Net Profit	2468.28 Cr	2957.93 Cr	2513.47 Cr	4077.25 Cr
Profit Balance B/F	12479.7 Cr	14961.7 Cr	17534.8 Cr	19634.2 Cr
Appropriations	14948 Cr	17919.6 Cr	20048.2 Cr	23711.5 Cr
Other Appropriation	-13.71 Cr	384.87 Cr	414.02 Cr	760.64 Cr
Equity Dividend %	250	250	425	650
Earnings Per Share	30.61	33.33	30.6	46
Adjusted EPS	30.61	33.33	30.6	46

Consolidated Standalone

CONSOLIDATED CASH FLOW FOR CIPLA LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	3290.06 Cr	3675.39 Cr	4220.77 Cr	5896.72 Cr
Adjustment	1130.91 Cr	967.47 Cr	878.19 Cr	640.77 Cr
Changes In working Capital	371.66 Cr	-177.46 Cr	-559.42 Cr	-806.1 Cr
Cash Flow after changes in Working Capital	4792.63 Cr	4465.4 Cr	4539.54 Cr	5731.39 Cr
Cash Flow from Operating Activities	3755.2 Cr	3325.9 Cr	3237.65 Cr	4133.91 Cr
Cash Flow from Investing Activities	-2387.18 Cr	-1871.88 Cr	-2388.51 Cr	-2988.03 Cr
Cash Flow from Financing Activitie	-1329.9 Cr	-1599.79 Cr	-958.29 Cr	-1200.43 Cr
Net Cash Inflow / Outflow	38.12 Cr	-145.77 Cr	-109.15 Cr	-54.55 Cr
Opening Cash & Cash Equivalents	742.38 Cr	790.43 Cr	658.11 Cr	561.33 Cr
Effect of Foreign Exchange Fluctuations	12.79 Cr	13.45 Cr	12.37 Cr	5.56 Cr
Closing Cash & Cash Equivalent	793.29 Cr	658.11 Cr	561.33 Cr	512.34 Cr

STANDALONE CASH FLOW FOR CIPLA LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	3350.66 Cr	3905.08 Cr	3685.17 Cr	5432.14 Cr
Adjustment	511.27 Cr	73.26 Cr	269.57 Cr	-342.91 Cr
Changes In working Capital	550.33 Cr	-270.88 Cr	164.57 Cr	-138.3 Cr
Cash Flow after changes in Working Capital	4412.26 Cr	3707.46 Cr	4119.31 Cr	4950.93 Cr
Cash Flow from Operating Activities	3460.31 Cr	2773.43 Cr	3035.05 Cr	3726.77 Cr
Cash Flow from Investing Activities	-3360.45 Cr	-2463.73 Cr	-2757.95 Cr	-2882.82 Cr
Cash Flow from Financing Activitie	-65.8 Cr	-426.72 Cr	-424.77 Cr	-708.83 Cr
Net Cash Inflow / Outflow	34.06 Cr	-117.02 Cr	-147.67 Cr	135.12 Cr
Opening Cash & Cash Equivalents	261.54 Cr	294.72 Cr	177.29 Cr	29.48 Cr
Effect of Foreign Exchange Fluctuations	-88 Lk	-41 Lk	-14 Lk	-8 Lk
Closing Cash & Cash Equivalent	294.72 Cr	177.29 Cr	29.48 Cr	164.52 Cr

Consolidated Standalone

CONSOLIDATED BALANCE SHEET FOR CIPLA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	161.29 Cr	161.36 Cr	161.43 Cr	161.47 Cr
Equity - Authorised	175 Cr	175 Cr	175 Cr	175 Cr
Equity - Issued	161.29 Cr	161.36 Cr	161.43 Cr	161.47 Cr
Equity Paid Up	161.29 Cr	161.36 Cr	161.43 Cr	161.47 Cr
Face Value	2	2	2	2
Total Reserves	18123.2 Cr	20636.3 Cr	23184.5 Cr	26458.4 Cr
Securities Premium	1613.31 Cr	1631.69 Cr	1652.77 Cr	1672.84 Cr
Capital Reserves	-165.95 Cr	-167.04 Cr	-167.04 Cr	-264.24 Cr
Profit & Loss Account Balance	13537 Cr	15669.1 Cr	18057 Cr	21438.8 Cr
General Reserves	3144.64 Cr	3144.8 Cr	3144.92 Cr	3145 Cr
Reserve excluding Revaluation Reserve	18123.2 Cr	20636.3 Cr	23184.5 Cr	26458.4 Cr
Shareholder's Funds	18326.5 Cr	20841.7 Cr	23407.8 Cr	26706.4 Cr
Minority Interest	259.06 Cr	275.69 Cr	305.76 Cr	95.9 Cr
Secured Loans	355.32 Cr	376.2 Cr	332.46 Cr	0
Term Loans - Banks	355.32 Cr	376.2 Cr	332.46 Cr	0
Unsecured Loans	847.43 Cr	40.04 Cr	-332.46 Cr	0
Loans - Banks	1065.51 Cr	54.6 Cr	11.78 Cr	0
Deferred Tax Assets / Liabilities	-18.08 Cr	-204.87 Cr	-293.26 Cr	-402.51 Cr
Deferred Tax Assets	675.63 Cr	818.15 Cr	795.55 Cr	886.55 Cr
Deferred Tax Liability	657.55 Cr	613.28 Cr	502.29 Cr	484.04 Cr
Other Long Term Liabilities	359.22 Cr	310.45 Cr	374.63 Cr	355.17 Cr
Long Term Provisions	116.17 Cr	100.22 Cr	102.16 Cr	129.26 Cr
Total Non-Current Liabilities	1660.06 Cr	622.04 Cr	183.53 Cr	81.92 Cr
Trade Payables	2066.82 Cr	2508.1 Cr	2457.05 Cr	2473.98 Cr
Sundry Creditors	2066.82 Cr	2508.1 Cr	2457.05 Cr	2473.98 Cr
Other Current Liabilities	1093.62 Cr	769.81 Cr	1085.07 Cr	890.98 Cr
Bank Overdraft / Short term credit	0	0	0	89 Lk
Advances received from customers	44.66 Cr	76.93 Cr	63.64 Cr	13.57 Cr
Short Term Borrowings	334.73 Cr	393.34 Cr	187.9 Cr	247.02 Cr
Secured ST Loans repayable on Demands	37.04 Cr	0	96.97 Cr	91.77 Cr
Working Capital Loans- Sec	37.04 Cr	0	96.97 Cr	91.77 Cr
Short Term Provisions	1096.38 Cr	1241.62 Cr	1303.25 Cr	1633.79 Cr
Provision for Tax	18.06 Cr	20.62 Cr	16.58 Cr	22.03 Cr
Provision for post retirement benefits	282.43 Cr	265.43 Cr	0	0
Total Current Liabilities	4591.55 Cr	4912.87 Cr	5033.27 Cr	5245.77 Cr
Total Liabilities	24837.2 Cr	26652.3 Cr	29006.7 Cr	32130 Cr
Gross Block	15735.9 Cr	16975.6 Cr	17204.8 Cr	18155.3 Cr
Less: Accumulated Depreciation	6305.64 Cr	7318.07 Cr	7994.72 Cr	8568.16 Cr
Less: Impairment of Assets	36.46 Cr	35.6 Cr	109.39 Cr	93.57 Cr
Net Block	9393.77 Cr	9621.91 Cr	9100.65 Cr	9493.61 Cr
Capital Work in Progress	570.84 Cr	382.9 Cr	689.17 Cr	864.32 Cr
Non Current Investments	545.43 Cr	417.05 Cr	572.52 Cr	642.21 Cr
Long Term Investment	545.43 Cr	417.05 Cr	572.52 Cr	642.21 Cr
Quoted	190.33 Cr	0	0	0
Unquoted	355.1 Cr	417.05 Cr	572.52 Cr	642.21 Cr
Long Term Loans & Advances	645.57 Cr	695.49 Cr	845.11 Cr	838.53 Cr
Other Non Current Assets	74.03 Cr	440.83 Cr	60.38 Cr	447.93 Cr
Total Non-Current Assets	11627.7 Cr	11941.5 Cr	11731.8 Cr	12688.6 Cr
Currents Investments	2286.37 Cr	2194.97 Cr	3089.86 Cr	4807.01 Cr
Quoted	2286.37 Cr	2194.97 Cr	3089.86 Cr	4807.01 Cr
Unquoted	355.1 Cr	417.05 Cr	572.52 Cr	642.21 Cr
Inventories	4669.18 Cr	5350.24 Cr	5156.43 Cr	5237.95 Cr
Raw Materials	1795.44 Cr	1701.19 Cr	1615.83 Cr	1619.47 Cr
Work-in Progress	831.22 Cr	821.85 Cr	831.74 Cr	786.92 Cr
Finished Goods	1001.74 Cr	1352.8 Cr	1370.57 Cr	1261.12 Cr
Stores and Spare	67.66 Cr	83.1 Cr	106.98 Cr	109.98 Cr
Sundry Debtors	3445.68 Cr	3424.44 Cr	4057 Cr	4770.66 Cr
Debtors more than Six months	0	318.69 Cr	280.83 Cr	221.45 Cr
Debtors Others	3677.22 Cr	3286.46 Cr	3901.47 Cr	4688.5 Cr
Cash and Bank	1401.23 Cr	1928.48 Cr	1564.62 Cr	874.97 Cr
Cash in hand	87 Lk	1 Cr	76 Lk	54 Lk
Balances at Bank	1388.86 Cr	1918.46 Cr	1559.37 Cr	743.2 Cr
Other Current Assets	376.02 Cr	305.56 Cr	373.99 Cr	567.64 Cr
Interest accrued on Investments	0	23.61 Cr	43.36 Cr	43.26 Cr
Prepaid Expenses	105.54 Cr	110.61 Cr	112.9 Cr	132.91 Cr
Short Term Loans and Advances	1031.03 Cr	1507.14 Cr	2563.16 Cr	3134.22 Cr
Advances recoverable in cash or in kind	170.34 Cr	202.02 Cr	211.47 Cr	211.8 Cr
Corporate Deposits	3.83 Cr	0	0	0
Total Current Assets	13209.5 Cr	14710.8 Cr	16805.1 Cr	19392.4 Cr
Net Current Assets (Including Current Investments)	8617.96 Cr	9797.96 Cr	11771.8 Cr	14146.7 Cr
Total Assets	24837.2 Cr	26652.3 Cr	29006.7 Cr	32130 Cr
Contingent Liabilities	622.09 Cr	742.84 Cr	566.55 Cr	633.96 Cr
Total Debt	1755.56 Cr	824.14 Cr	520.36 Cr	247.02 Cr
Book Value	226.73	257.78	289.24	329.72
Adjusted Book Value	226.73	257.78	289.24	329.72

STANDALONE BALANCE SHEET FOR CIPLA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	161.29 Cr	161.36 Cr	161.43 Cr	161.47 Cr
Equity - Authorised	175 Cr	175 Cr	175 Cr	175 Cr
Equity - Issued	161.29 Cr	161.36 Cr	161.43 Cr	161.47 Cr
Equity Paid Up	161.29 Cr	161.36 Cr	161.43 Cr	161.47 Cr
Face Value	2	2	2	2
Total Reserves	19730.6 Cr	22315.3 Cr	24437.6 Cr	27768.4 Cr
Securities Premium	1613.31 Cr	1631.69 Cr	1652.77 Cr	1672.84 Cr
Capital Reserves	8 Lk	8 Lk	8 Lk	8 Lk
Profit & Loss Account Balance	14961.7 Cr	17534.8 Cr	19634.2 Cr	22950.8 Cr
General Reserves	3144.64 Cr	3144.8 Cr	3144.92 Cr	3145 Cr
Reserve excluding Revaluation Reserve	19730.6 Cr	22315.3 Cr	24437.6 Cr	27768.4 Cr
Shareholder's Funds	19927.6 Cr	22513.6 Cr	24638.1 Cr	27973.9 Cr
Deferred Tax Assets / Liabilities	104.91 Cr	55.96 Cr	36.13 Cr	32.64 Cr
Deferred Tax Assets	224.15 Cr	257.73 Cr	249.95 Cr	211.07 Cr
Deferred Tax Liability	329.06 Cr	313.69 Cr	286.08 Cr	243.71 Cr
Other Long Term Liabilities	143.36 Cr	396.13 Cr	140.78 Cr	90.18 Cr
Long Term Provisions	95.97 Cr	78.92 Cr	81.73 Cr	94.24 Cr
Total Non-Current Liabilities	344.24 Cr	531.01 Cr	258.64 Cr	217.06 Cr
Trade Payables	1495.49 Cr	1378.93 Cr	1594.12 Cr	1684.64 Cr
Sundry Creditors	1495.49 Cr	1378.93 Cr	1594.12 Cr	1684.64 Cr
Other Current Liabilities	571.32 Cr	394.77 Cr	458.88 Cr	423.08 Cr
Bank Overdraft / Short term credit	5.08 Cr	0	1.18 Cr	0
Advances received from customers	38.91 Cr	66.99 Cr	55.47 Cr	10.66 Cr
Short Term Provisions	625.13 Cr	630.79 Cr	646.74 Cr	754.53 Cr
Provision for Tax	4.57 Cr	0	0	7.29 Cr
Provision for post retirement benefits	157.55 Cr	127.49 Cr	0	0
Total Current Liabilities	2691.94 Cr	2404.49 Cr	2699.74 Cr	2862.25 Cr
Total Liabilities	22963.7 Cr	25449.1 Cr	27596.5 Cr	31053.2 Cr
Gross Block	6951.98 Cr	6284.86 Cr	7733.72 Cr	7904.04 Cr
Less: Accumulated Depreciation	2997.73 Cr	2942.45 Cr	3909.24 Cr	4261 Cr
Less: Impairment of Assets	11.59 Cr	14.72 Cr	77.2 Cr	39.9 Cr
Net Block	3942.66 Cr	3327.69 Cr	3747.28 Cr	3603.14 Cr
Capital Work in Progress	275.04 Cr	169.22 Cr	441.53 Cr	580.9 Cr
Non Current Investments	7844.78 Cr	8998.23 Cr	9137.91 Cr	9410.17 Cr
Long Term Investment	7844.78 Cr	8998.23 Cr	9137.91 Cr	9410.17 Cr
Unquoted	7844.78 Cr	8998.23 Cr	9137.91 Cr	9410.17 Cr
Long Term Loans & Advances	596.1 Cr	542.3 Cr	748.77 Cr	1904.67 Cr
Other Non Current Assets	32.91 Cr	2173.57 Cr	25.41 Cr	442.69 Cr
Total Non-Current Assets	12771.6 Cr	15255.6 Cr	14225.3 Cr	16146.4 Cr
Currents Investments	2004.84 Cr	2038.8 Cr	2771.44 Cr	4383.59 Cr
Quoted	2004.84 Cr	2038.8 Cr	2771.44 Cr	4383.59 Cr
Unquoted	7844.78 Cr	8998.23 Cr	9137.91 Cr	9410.17 Cr
Inventories	3085.81 Cr	3199.05 Cr	3277.36 Cr	3254.28 Cr
Raw Materials	1335.23 Cr	1209.41 Cr	1173.74 Cr	1232.35 Cr
Work-in Progress	661.68 Cr	647.53 Cr	658.7 Cr	650.55 Cr
Finished Goods	519.55 Cr	663.12 Cr	643.14 Cr	593.41 Cr
Stores and Spare	54.86 Cr	65.82 Cr	91.94 Cr	96.33 Cr
Sundry Debtors	3035.37 Cr	1939.62 Cr	2888.49 Cr	2681.75 Cr
Debtors more than Six months	0	275.81 Cr	206.37 Cr	167.72 Cr
Debtors Others	3131.01 Cr	2688.73 Cr	2783.36 Cr	2619.59 Cr
Cash and Bank	874.8 Cr	1428.03 Cr	966.46 Cr	333.2 Cr
Cash in hand	65 Lk	80 Lk	61 Lk	50 Lk
Balances at Bank	862.65 Cr	1419.62 Cr	965.81 Cr	206.02 Cr
Other Current Assets	292.42 Cr	238.17 Cr	326.65 Cr	490.98 Cr
Interest accrued on Investments	7 Cr	23.61 Cr	43.34 Cr	43.22 Cr
Prepaid Expenses	64.95 Cr	74.82 Cr	69.83 Cr	89.1 Cr
Short Term Loans and Advances	898.94 Cr	1349.75 Cr	3140.73 Cr	3714.04 Cr
Advances recoverable in cash or in kind	109.09 Cr	121.74 Cr	110.13 Cr	99.08 Cr
Corporate Deposits	3.19 Cr	0	0	0
Total Current Assets	10192.2 Cr	10193.4 Cr	13371.1 Cr	14857.8 Cr
Net Current Assets (Including Current Investments)	7500.24 Cr	7788.93 Cr	10671.4 Cr	11995.6 Cr
Total Assets	22963.7 Cr	25449.1 Cr	27596.5 Cr	31053.2 Cr
Contingent Liabilities	1700.79 Cr	619.71 Cr	552.8 Cr	614.78 Cr
Book Value	246.66	278.59	304.76	345.95
Adjusted Book Value	246.66	278.59	304.76	345.95

Consolidated Standalone

FINANCIAL RATIOS (CONSOLIDATED) FOR CIPLA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	29.82	31.19	34.71	51.05
CEPS(Rs)	42.21	44.76	49.65	64.49
DPS(Rs)	5	5	8.5	13
Book NAV/Share(Rs)	226.73	257.78	289.24	329.72
Tax Rate(%)	27.01	26.73	29.79	27.12
Margin Ratios
Core EBITDA Margin(%)	14.82	15.18	16.13	17.76
EBIT Margin(%)	12.22	12.11	13.41	16.35
Pre Tax Margin(%)	11.66	11.75	13.05	16.1
PAT Margin (%)	8.51	8.61	9.17	11.73
Cash Profit Margin (%)	12.06	12.15	12.95	14.7
Performance Ratios
ROA(%)	9.95	9.94	10.19	13.59
ROE(%)	14.13	13.1	12.85	16.63
ROCE(%)	17.85	17.24	18.19	22.77
Asset Turnover(x)	1.17	1.15	1.11	1.16
Sales/Fixed Asset(x)	1.84	1.82	1.81	2
Working Capital/Sales(x)	3.28	3.03	2.63	2.5
Efficiency Ratios
Fixed Capital/Sales(x)	0.54	0.55	0.55	0.5
Receivable days	47.44	42.19	44.13	45.49
Inventory Days	58.49	61.53	61.98	53.56
Payable days	54.19	98.28	109.81	103.64
Valuation Parameters
PER(x)	27.34	32.65	25.95	29.28
PCE(x)	19.31	22.75	18.14	23.18
Price/Book(x)	3.6	3.95	3.11	4.53
Yield(%)	0.61	0.49	0.94	0.87
EV/Net Sales(x)	3.45	3.72	3.15	4.66
EV/Core EBITDA(x)	14.84	16.77	13.02	17.06
EV/EBIT(x)	19.16	22.52	17.27	20.73
EV/CE(x)	2.66	3.04	2.47	4.45
M Cap / Sales	3.43	3.78	3.19	4.68
Growth Ratio
Net Sales Growth(%)	11.84	13.59	4.55	13.28
Core EBITDA Growth(%)	28.15	6.98	13.83	27.9
EBIT Growth(%)	45.26	4.31	15.23	39.63
PAT Growth(%)	55.23	6.59	10.78	46.55
EPS Growth(%)	55.46	4.61	11.28	47.06
Financial Stability Ratios
Total Debt/Equity(x)	0.1	0.04	0.02	0.01
Current Ratio(x)	2.88	2.99	3.34	3.7
Quick Ratio(x)	1.86	1.91	2.31	2.7
Interest Cover(x)	21.47	33.85	37.87	64.44
Total Debt/Mcap(x)	0.03	0.01	0.01	0

FINANCIAL RATIOS (STANDALONE) FOR CIPLA LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	30.61	33.33	30.6	46
CEPS(Rs)	37.34	39.04	37.98	53.28
DPS(Rs)	5	5	8.5	13
Book NAV/Share(Rs)	246.66	278.59	304.76	345.95
Tax Rate(%)	26.33	24.16	28.22	24.92
Margin Ratios
Core EBITDA Margin(%)	25.12	24.03	22.93	25.65
EBIT Margin(%)	23	25.51	21.01	28.41
Pre Tax Margin(%)	22.69	25.31	20.85	28.3
PAT Margin (%)	16.72	19.2	14.96	21.24
Cash Profit Margin (%)	20.4	22.48	18.57	24.61
Performance Ratios
ROA(%)	11.38	11.11	9.31	12.67
ROE(%)	13.25	12.7	10.49	14.14
ROCE(%)	18.19	16.84	14.71	18.88
Asset Turnover(x)	0.68	0.58	0.62	0.6
Sales/Fixed Asset(x)	2.19	2.12	2.19	2.24
Working Capital/Sales(x)	1.97	1.8	1.55	1.46
Efficiency Ratios
Fixed Capital/Sales(x)	0.46	0.47	0.46	0.45
Receivable days	81.52	64.81	62.84	58.15
Inventory Days	75.49	81.88	74.79	68.18
Payable days	58.17	133.14	132.39	155.96
Valuation Parameters
PER(x)	26.64	30.55	29.44	32.49
PCE(x)	21.83	26.09	23.71	28.05
Price/Book(x)	3.31	3.66	2.96	4.32
Yield(%)	0.61	0.49	0.94	0.87
EV/Net Sales(x)	4.67	6.17	4.54	7.26
EV/Core EBITDA(x)	16.47	20.02	16.88	21.66
EV/EBIT(x)	19.1	22.6	20.69	24.23
EV/CE(x)	2.82	3.17	2.6	4.3
M Cap / Sales	4.73	6.28	4.6	7.28
Growth Ratio
Net Sales Growth(%)	9.81	15.83	2.66	15.54
Core EBITDA Growth(%)	9.99	22.3	-2.94	45.81
EBIT Growth(%)	13.18	26.3	-9.49	64.05
PAT Growth(%)	6.48	31.53	-14.33	73.23
EPS Growth(%)	6.45	31.48	-14.37	73.19
Financial Stability Ratios
Current Ratio(x)	3.79	4.24	4.95	5.19
Quick Ratio(x)	2.64	2.91	3.74	4.05
Interest Cover(x)	75.34	132.68	128.33	245.3

SHARE HOLDING PATTERN FOR CIPLA LIMITED

Date	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters %	13.49	13.40	13.48	13.46	13.43	13.43	13.43	13.43	10.88	10.89
FII %	27.64	27.52	28.38	27.41	25.49	25.74	25.73	25.82	27.82	28.80
DII %	0.19	0.20	0.21	0.18	0.24	0.22	0.19	0.17	0.18	0.19
Public %	17.40	17.73	16.91	16.99	16.76	16.67	16.53	16.36	16.40	16.19

PEER COMPARISON FOR CIPLA LIMITED

No.	Name
1	AMBALAL SARABHAI ENTERPRISES LTD
2	Cipla Limited
3	Dr. Reddy's Laboratories Limited
4	Procter & Gamble Health Limited
5	J.K.PHARMACHEM LTD
6	Lupin Limited
7	Lyka Labs Limited
8	MESCO PHARMACEUTICALS LTD
9	Morepen Laboratories Limited
10	Piramal Enterprises Limited
11	Torrent Pharmaceuticals Limited
12	Abbott India Limited
13	GlaxoSmithKline Pharmaceuticals Limited
14	Sanofi India Limited
15	Pfizer Limited
16	Bliss GVS Pharma Limited
17	Alembic Limited
18	Unichem Laboratories Limited
19	AstraZeneca Pharma India Limited
20	GUJARAT THEMIS BIOSYN LTD
21	JB Chemicals & Pharmaceuticals Limited
22	TTK Healthcare Limited
23	Jagsonpal Pharmaceuticals Limited
24	Gufic Biosciences Limited
25	Sequent Scientific Limited
26	Albert David Limited
27	IOL Chemicals and Pharmaceuticals Limited
28	Wanbury Limited
29	Kopran Limited
30	Aarti Drugs Limited
31	Orchid Pharma Limited
32	Biofil Chemicals & Pharmaceuticals Limited
33	Marksans Pharma Limited
34	IPCA Laboratories Limited
35	Kilitch Drugs (India) Limited
36	Krebs Biochemicals and Industries Limited
37	Neuland Laboratories Limited
38	Ind-Swift Limited
39	Hester Biosciences Limited
40	Parenteral Drugs (India) Limited
41	Sun Pharmaceutical Industries Limited
42	Hikal Limited
43	Caplin Point Laboratories Limited
44	Aurobindo Pharma Limited
45	Natco Pharma Limited
46	Bal Pharma Limited
47	BDH INDUSTRIES LTD
48	Venus Remedies Limited
49	Jubilant Pharmova Limited
50	Themis Medicare Limited

CORPORATE ACTIONS FOR CIPLA LIMITED

Exchange Date	Purpose	Book Closure Dates
BSE 01-Oct-2024	Board Meeting - Quarterly Results	29-Oct-2024
BSE 04-Jul-2024	Board Meeting - Quarterly Results	26-Jul-2024
BSE 10-May-2024	Dividend - Rs.13.0000 per share(650%)Final Dividend
BSE 10-May-2024	AGM - Inter alia, approved:- 1. Recommended payment of final dividend of Rs. 13 per equity share (face value of Rs. 2 per equity share) for the financial year ended 31st March 2024. The dividend, upon approval by the shareholders, will be paid within 30 days from the date of the Annual General Meeting. The record date for the purpose of payment of final dividend, if declared, shall be 2nd August 2024. 2...	20-Aug-2024
BSE 19-Apr-2024	SAST - Acquisition of a business undertaking from Ivia Beaute Private Limited, India
BSE 05-Apr-2024	Board Meeting - Audited Results & Final Dividend	10-May-2024
BSE 20-Jan-2024	Board Meeting - Quarterly Results (Revised)	22-Jan-2024
BSE 03-Jan-2024	Board Meeting - Quarterly Results	25-Jan-2024
BSE 15-Dec-2023	SAST - Cipla Limited has entered into definitive agreements on 14th December 2023 to acquire additional stake in GoApptiv Private Limited.
BSE 04-Oct-2023	Board Meeting - Quarterly Results	27-Oct-2023
BSE 26-Jul-2023	SAST - GoApptiv Private Limited, an associate company of Cipla Limited has incorporated Pactiv Healthcare Private Limited, a wholly-owned subsidiary company w.e.f. 26th July, 2023.
BSE 21-Jul-2023	Dividend - Rs.8.5000 per share(425%)Final Dividend
BSE 20-Jul-2023	SAST - In furtherance to our earlier intimation dated 31st March, 2021, we wish to inform you that the National Company Law Tribunal, Mumbai vide its order dated 22nd June, 2023 (certified copy of which was received on 19th July, 2023), has approved the Scheme of Amalgamation for merger of Pharmasofttech Awacs Private Limited into Pharmarack Technologies Private Limited. Both these companies are subsidia...
BSE 04-Jul-2023	Board Meeting - Quarterly Results	26-Jul-2023
BSE 12-Apr-2023	Board Meeting - Audited Results & Quarterly Results & Final Dividend	12-May-2023
BSE 30-Dec-2022	SAST - We hereby notify that Cipla (EU) Limited, United Kingdom, wholly owned subsidiary of Cipla Limited, has entered into definitive agreements on 29th December 2022 for acquisition of ~10.35% of the registered share capital of Ethris GmbH, Germany.
BSE 29-Dec-2022	Board Meeting - Quarterly Results	25-Jan-2023
BSE 11-Oct-2022	Board Meeting - Quarterly Results	04-Nov-2022
BSE 30-Aug-2022	SAST - Cipla Limited hereby notify the Exchange that Cipla (EU) Limited, ("Cipla EU"), wholly owned subsidiary of the Company in UK has agreed to acquire an additional13.10% stake in Cipla (Jiangsu) Pharmaceutical Co. Ltd., a subsidiary of Cipla EU in China
BSE 08-Aug-2022	Dividend - Rs.5.0000 per share(250%)Dividend
BSE 08-Jul-2022	Board Meeting - Quarterly Results	29-Jul-2022
BSE 17-Jun-2022	SAST - Cipla has entered into definitive agreements on 17th June 2022 for the acquisition of 21.05% stake (on a fully diluted basis) in Achira Labs Private Limited.
BSE 19-Apr-2022	Board Meeting - Dividend & Audited Results	10-May-2022
BSE 04-Feb-2022	SAST - In compliance with the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit that in line with the commitment to enhance the share of renewable power source in its operation and to comply with regulatory requirement for being a 'captive user' under Indian electricity laws, Cipla Limited has en...
BSE 30-Dec-2021	Board Meeting - Quarterly Results	25-Jan-2022
BSE 15-Dec-2021	SAST - In compliance with the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit that in line with the commitment to enhance the share of renewable power source in its operation and to comply with regulatory requirement for being a 'captive user' under electricity laws, Cipla Limited has entered i...
BSE 03-Nov-2021	SAST - Please find enclosed update on intimations dated 13th November, 2018 and 8th February, 2019 on acquisition agreement entered between InvaGen Pharmaceuticals Inc. and Avenue Therapeutics Inc.
BSE 01-Oct-2021	Board Meeting - Quarterly Results	26-Oct-2021
BSE 21-Sep-2021	SAST - Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations, 2015), we hereby notify that Cipla Limited has subscribed to 5% equity shares (on a fully diluted basis) of Swasth Digital Health Foundation, a not-for-profit organisation, with an aim to leverage digital technologies and build healthcare tech infrastructure. The req...

CORPORATE ANNOUNCEMENTS FOR CIPLA LIMITED

Exchange Date	Category File	Description
BSE 30-Oct-2024	General Announcements FILE	Update On USFDA Inspection At Company''s Manufacturing Facility In Goa India Update on USFDA inspection at Companys manufacturing facility in Goa India
BSE 29-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Pursuant to Regulation 30(6) of the SEBI 9Listing Obligations and Disclosure) Requirements 2015 the audio recording of the earnings conference call for Q1FY25 held today is available on the Companys website at https://www.cipla.com/audio/12578
BSE 29-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Please find the attached newspaper publication
BSE 29-Oct-2024	Outcome FILE	Board Meeting Outcome for Outcome Of Board Meeting Dated 29Th October 2024 Outcome of Board meeting dated 29th October 2024
BSE 29-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Investor Presentation Please find the attached investor presentation dated 29th October 2024
BSE 29-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Press Release / Media Release Please find the attached press release dated 29th October 2024
BSE 29-Oct-2024	Outcome FILE	Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended 30Th September 2024 Unaudited financial results (standalone and consolidated) for the quarter and half year ended 30th September 2024
BSE 25-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Updates on Acquisition Update on acquisition of additional equity interest in Cipla (Jiangsu) Pharmaceuticals Co. Ltd.
BSE 17-Oct-2024	General Announcements FILE	Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 ('SEBI Listing Regulations 2015') Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations 2015)
BSE 14-Oct-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot Result of the Postal Ballot along with Scrutiniser report
BSE 11-Oct-2024	General Announcements FILE	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Certificate under Regulation 74(5) of SEBI (DP) Regulation 2018
BSE 09-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we are enclosing herewith the schedule of Earnings Conference Call to be held on 29th October 2024.
BSE 05-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS In compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby notify that the Operations and Administrative Committee of the Company on 5th October 2024 has allotted 28 465 equity shares of INR 2 each pursuant to exercise of employee stock options/stock appreciation rights under the Employee Stock Option Scheme 2013-A and Cipla Employee Stock Appreciation Rights Scheme 2021 of the Company.
BSE 01-Oct-2024	Intimation FILE	Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (''Listing Regulations'') CIPLA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2024 inter alia to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2024.
BSE 25-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Acquisition Intimation under Regulation 30 read with Schedule lll of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
BSE 14-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper advertisement for Notice of Postal Ballot and e-voting information
BSE 13-Sep-2024	Intimation FILE	Shareholder Meeting / Postal Ballot-Notice of Postal Ballot Notice of Postal Ballot dated 3rd September 2024
BSE 12-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS In compliance with the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby notify that the Operations and Administrative Committee of the Company on 12th September 2024 has allotted 7 059 fully paid up equity shares of the INR 2 each pursuant to exercise of employee stock options/ stock appreciation rights under the Employee Stock Option Scheme 2013-A and Cipla Employee Stock Appreciation Rights Scheme 2021 of the Company.
BSE 04-Sep-2024	General Announcements FILE	Corrigendum - Outcome Of Board Meeting Held On 3Rd September 2024 Corrigendum - Outcome of Board meeting held on 3rd September 2024
BSE 03-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Change in Directorate Change in Directors of the Company
BSE 03-Sep-2024	Outcome FILE	Board Meeting Outcome for Outcome Of Board Meeting Held On 3Rd September 2024 Outcome of Board meeting held on 3rd September 2024
BSE 02-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Change in Directorate Mr. Adil Zainulbhai and Mr. Ashok Sinha are completing their second term as an independent director on 2nd September 2024.
BSE 30-Aug-2024	General Announcements FILE	Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
BSE 30-Aug-2024	General Announcements FILE	Transcript Of The 88Th Annual General Meeting Please find enclosed the transcript of the 88th Annual General Meeting of the Company held on Tuesday 20th August 2024 through video conferencing/ other audio-visual means.
BSE 25-Aug-2024	General Announcements FILE	Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
BSE 20-Aug-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report Details of voting results of the 88th Annual General Meeting of the Company and Scrutinisers report
BSE 20-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Change in Management Retirement of Mr. S. Radhakrishnan as Non-Executive Director of the Company
BSE 20-Aug-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Outcome of AGM Proceedings of the 88th Annual General Meeting.
BSE 20-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that the Company will hold one-on-one meetings or group meetings with investors in the United States of America as part of a Non-Deal Roadshow.
BSE 19-Aug-2024	General Announcements FILE	Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

INSIDER TRADING FOR CIPLA LIMITED

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 21-Aug-2024 21-Aug-2024	Sell Market	2,000 @ 0.00 (0.00 %)	Anusha Jain
BSE 12-Aug-2024 12-Aug-2024	Sell Market	3,000 @ 0.00 (0.00 %)	Anusha Jain
BSE 21-Dec-2022 21-Dec-2022	Buy Market	1,000 @ 0.00 (0.00 %)	Vidya Prabhakar Rote jointly with Kiran Rote
BSE 13-Feb-2023 13-Feb-2023	Buy Off Market	10,000 @ 0.00 (0.00 %)	Shachi Malpani
BSE 11-Mar-2022 11-Mar-2022	Sell Market	2,000 @ 0.00 (0.00 %)	Anusha Dinesh Jain

BULK BLOCK DEALS FOR CIPLA LIMITED

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 25-Jan-2024	Sell BLOCK	1,188,318 @ 1417.35	BNP PARIBAS ARBITRAGE
BSE 25-Jan-2024	Buy BLOCK	1,188,318 @ 1417.35	SOCIETE GENERALE
BSE 18-Jan-2024	Sell BLOCK	142,206 @ 1293.50	JUPITER SOUTH ASIA INVESTMENT COMPANY LIMITED
BSE 18-Jan-2024	Buy BLOCK	142,206 @ 1293.50	THE JUPITER GLOBAL FUND-JUPITER INDIA SELECT
BSE 25-Oct-2022	Sell BLOCK	409,513 @ 1146.45	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 25-Oct-2022	Buy BLOCK	409,513 @ 1146.45	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 17-Oct-2022	Sell BLOCK	643,544 @ 1108.90	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 17-Oct-2022	Buy BLOCK	643,544 @ 1108.90	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 11-Oct-2022	Sell BLOCK	629,290 @ 1118.85	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 11-Oct-2022	Buy BLOCK	629,290 @ 1118.85	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 19-Sep-2022	Sell BLOCK	428,036 @ 1043.50	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 19-Sep-2022	Buy BLOCK	428,036 @ 1043.50	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 01-Aug-2022	Sell BLOCK	571,776 @ 977.40	ISHARES INDIA INDEX MAURITIUS COMPANY
BSE 01-Aug-2022	Buy BLOCK	571,776 @ 977.40	ISHARES MSCI INDIA ETF
BSE 18-Jul-2022	Buy BLOCK	83,265 @ 966.05	ISHARES INDIA 50 ETF
BSE 18-Jul-2022	Sell BLOCK	575,211 @ 966.05	ISHARES INDIA INDEX MAURITIUS COMPANY
BSE 18-Jul-2022	Sell BLOCK	83,265 @ 966.05	ISHARES INDIA MAURITIUS CO
BSE 18-Jul-2022	Buy BLOCK	575,211 @ 966.05	ISHARES MSCI INDIA ETF
BSE 04-May-2022	Buy BLOCK	542,295 @ 976.60	ISHARES CORE MSCI TOTAL INTERNATIONAL STOCK ETF
BSE 04-May-2022	Sell BLOCK	542,295 @ 976.60	ISHARES CORE TOTAL INTERNATIONAL STOCK MAURITIUS CO
BSE 15-Feb-2022	Sell BULK	6,723,252 @ 910.15	M K HAMIED
BSE 15-Feb-2022	Sell BULK	13,446,504 @ 910.05	Y K HAMIED
BSE 20-Oct-2021	Sell BLOCK	440,841 @ 906.20	ISHARES EMERGING MARKETS INDEX MAURITIUS CO
BSE 20-Oct-2021	Buy BLOCK	440,841 @ 906.20	ISHARES MSCI EMERGING MARKETS ETF
BSE 11-Oct-2021	Sell BLOCK	440,841 @ 917.10	ISHARES EMERGING MARKETS INDEX MAURITIUS CO
BSE 11-Oct-2021	Buy BLOCK	440,841 @ 917.10	ISHARES MSCI EMERGING MARKETS ETF
BSE 23-Sep-2021	Sell BLOCK	448,716 @ 963.50	ISHARES EMERGING MARKETS INDEX MAURITIUS CO
BSE 23-Sep-2021	Buy BLOCK	448,716 @ 963.50	ISHARES MSCI EMERGING MARKETS ETF

DIVIDEND BY CIPLA LIMITED

Ex Dividend Date	Dividend Type	Dividend
02-Aug-2024	DIVIDEND	13
21-Jul-2023	DIVIDEND	8.5
08-Aug-2022	DIVIDEND	5
09-Aug-2021	DIVIDEND	5

SPLIT / BONUS BY CIPLA LIMITED

No Split / Bonus details found

Data feed Source : www.accordfintech.com, NSE DATA Feed & BSE Data Feed

Facebook

Twitter

To TOP

Cipla Limited

Cipla Limited share price

CONSOLIDATED QUARTERLY RESULT FOR CIPLA LIMITED

STANDALONE QUARTERLY RESULT FOR CIPLA LIMITED

CONSOLIDATED ANNUAL RESULT FOR CIPLA LIMITED

STANDALONE ANNUAL RESULT FOR CIPLA LIMITED

CONSOLIDATED PROFIT / LOSS FOR CIPLA LIMITED

STANDALONE PROFIT / LOSS FOR CIPLA LIMITED

CONSOLIDATED CASH FLOW FOR CIPLA LIMITED

STANDALONE CASH FLOW FOR CIPLA LIMITED

CONSOLIDATED BALANCE SHEET FOR CIPLA LIMITED

STANDALONE BALANCE SHEET FOR CIPLA LIMITED

FINANCIAL RATIOS (CONSOLIDATED) FOR CIPLA LIMITED

FINANCIAL RATIOS (STANDALONE) FOR CIPLA LIMITED

SHARE HOLDING PATTERN FOR CIPLA LIMITED

PEER COMPARISON FOR CIPLA LIMITED

CORPORATE ACTIONS FOR CIPLA LIMITED

CORPORATE ANNOUNCEMENTS FOR CIPLA LIMITED

INSIDER TRADING FOR CIPLA LIMITED

BULK BLOCK DEALS FOR CIPLA LIMITED

DIVIDEND BY CIPLA LIMITED

SPLIT / BONUS BY CIPLA LIMITED